New products lead Nicholas' growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

New products lead Nicholas' growth

Oct 19, 2000

Nicholas Piramal has reported an above average topline growth of 17% (vis–a–vis the overall domestic pharmaceutical growth of 10.8%) primarily due to introduction of new products such as Rejoint as well as Omnatax and Haemaccel which were acquired from Hoechst Marrion last year. Of the 19% growth in formulation sales in the second quarter almost 9% was from the acquired brands. Vitamin A which contributed around 13% to the company's turnover showed a growth of 10%. Besides, the company has been a beneficiary of the price hike that would yield Rs 40 m in the current year.

(Rs m) 2QFY00 2QFY01 Change
Sales 1229.10 1441.60 17.3%
Other Income 41.90 19.50 -53.5%
Expenditure 1057.70 1209.50 14.4%
Operating Profit (EBDIT) 171.40 232.10 35.4%
Operating Profit Margin (%) 13.95% 16.10%  
Interest 28.70 3.80 -86.8%
Depreciation 24.90 33.40 34.1%
Profit before Tax 159.70 214.40 34.3%
Other Adjustments      
Tax 18.50 29.80 61.1%
Profit after Tax/(Loss) 141.20 184.60 30.7%
Net profit margin (%) 11.49% 12.81%  
Earnings Per Share 16.21 21.19  

The company's R & D is focussing on five New Chemical Entities of which two are in the cardiovascular segment, one addresses the anti–cancer segment, one addresses the anti–diabetic segment and one for the fungal segment. These are expected to take around one and a half years more before the company reaches the stage of clinical trials.

However, the company's plans to float a US $ 70m –100m ADR issue have been deferred. The resources were to be used for upgrading its research for Mulund and setting up a a clinical research facility. A part of the proceeds was to be used to fund acquisitions both domestic and overseas. The managment was of the view that the company would raise resources via borrowings and tighten working capital management.

The stock quotes a price of Rs 312, which implies an earnings multiple of 14.7 times FY01 earnings.

Equitymaster requests your view! Post a comment on "New products lead Nicholas' growth ". Click here!


More Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 28, 2020 (Close)


  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks